SNDX Syndax Pharmaceuticals Inc.

11.35
-0.06  -1%
Previous Close 11.41
Open 11.49
Price To book 2.31
Market Cap 252196750
Shares 22,219,978
Volume 64,027
Short Ratio 7.09
Av. Daily Volume 79,236

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 part of Phase 1b/2 trial recently initiated - as noted March 2, 2017.
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 2 trial to advance to second stage of trial - noted May 16, 2017. Poster presentation at ASCO June 3, 2017.
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC)
Phase 3 PFS data due by the end of 2017.
E2112
HR+, HER2- breast cancer

Latest News

  1. Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference
  2. The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
  3. Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
  4. Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  5. Edited Transcript of SNDX earnings conference call or presentation 10-Aug-17 8:30pm GMT
  6. Syndax reports 2Q loss
  7. Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update
  8. Investor Network: Syndax Pharmaceuticals Inc to Host Earnings Call
  9. Why Earnings Season Could Be Great for Syndax Pharmaceuticals (SNDX)
  10. Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017
  11. 3 Under-the-Radar Stocks in the Healthcare Sector
  12. Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy
  13. Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
  14. Edited Transcript of SNDX earnings conference call or presentation 8-May-17 8:30pm GMT
  15. ETFs with exposure to Syndax Pharmaceuticals, Inc. : June 16, 2017
  16. Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
  17. Why Syndax Shares Are Rallying